Key result
High serum profilin-1 linked to worse survival and more CV events in CKD.
Why the study?
The association of serum profilin-1 levels with fatal and nonfatal cardiovascular events in patients with stage 1-5 chronic kidney disease was not previously investigated.
Are high serum profilin-1 levels associated with increased fatal and nonfatal cardiovascular events and reduced survival in patients with stage 1-5 CKD?
Cohort
Are high serum profilin-1 levels associated with increased fatal and nonfatal cardiovascular events and reduced survival in patients with stage 1-5 CKD?
p-value: p=<.001
Serum profilin-1 is independently associated with endothelial dysfunction, cardiovascular events, and survival in patients with CKD, suggesting its potential as a biomarker for cardiovascular risk in this population.
Serum profilin-1 may refine CVE risk stratification in CKD; hypothesis-generating and requires prospective validation before clinical use.
BACKGROUND: Profilin-1 is a ubiquitous, actin-binding protein that plays an important role in the regulation of actin polymerization and cytoskeleton remodelling and contributes to vascular dysfunction. We conducted this study to investigate the association of serum profilin-1 levels with fatal and nonfatal CVE in a cohort of patients with stage 1-5 CKD. MATERIALS AND METHODS: Serum concentrations of profilin-1 levels were determined by enzyme-linked immunosorbent assay. Endothelium-dependent vasodilatation (flow-mediated dilatation [FMD]) and endothelium-independent vasodilatation (nitroglycerine-mediated dilatation [NMD]) of the brachial artery were assessed noninvasively, using high-resolution ultrasound. RESULTS: Both fatal and nonfatal CVE were significantly higher in patients with high profilin-1 levels. Kaplan-Meier survival curves showed that patients with profilin-1 below the median value (114 pg/mL) had higher cumulative survival compared with patients who had profilin-1 levels above the median value (log-rank test, P < .001). CONCLUSIONS: This is the first study that demonstrates the serum profilin-1 is independently associated with endothelial dysfunction, cardiovascular events and survival in patients with CKD.
No takes yet. Share an insight, caveat, or question.
Eroğlu et al. (2017) conducted a cohort in Stage 1-5 chronic kidney disease. High serum profilin-1 levels (>114 pg/mL) vs. Low serum profilin-1 levels (≤114 pg/mL) was evaluated on Cumulative survival and fatal and nonfatal cardiovascular events (p=<.001). High serum profilin-1 levels (>114 pg/mL) were associated with significantly lower cumulative survival and higher fatal and nonfatal cardiovascular events in patients with CKD (P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: